Navigation Links
SeraCare Reports Second Quarter Fiscal Year 2011 Financial Results

MILFORD, Mass., May 12, 2011 /PRNewswire/ -- SeraCare Life Sciences, Inc. (NASDAQ: SRLS), a global life sciences company providing vital products and services to facilitate the discovery, development and production of human diagnostics and therapeutics, today reported operational and financial results for its second quarter of fiscal year 2011, ended March 31, 2011.


"In the second quarter of fiscal 2011, we significantly expanded our efforts to upgrade the sales and marketing organization, a central component of our strategy to drive future revenue growth," said Susan Vogt, President and Chief Executive Officer of SeraCare. "This group will operate under the leadership of Sean O'Connor, SeraCare's new Vice President of Sales and Marketing. We anticipate that when this sales force initiative is completed at the end of this calendar year, we will have upgraded more than 50 percent of our sales team with new, highly experienced representatives. We also recently made strategic changes to our Board of Directors with the election of two new, outstanding members, Kevin Hrusovsky and Joseph Nemmers. Kevin and Joe bring a wealth of industry experience to the Board and I look forward to working closely with them."  

"During the second quarter, SeraCare continued to experience a moderation in revenues due to the ongoing sales force realignment, the conversion of a key customer to a new, jointly developed, custom-manufactured bulk product and the expiration of certain government contracts," said Gregory Gould, Chief Financial Officer. "As a result, we believe the second half of fiscal year 2011 will continue to be a time of transition for the organization; however, we anticipate a return to growth during the first half of fiscal year 2012. We also remain committed to our long-term strategic goal of doubling SeraCare's revenues over the next three to four years."

SeraCare reported revenue of $11.0 million for the quarter ended March 31, 2011 compared to $12.9 million for the same quarter of the prior year, reflecting a 14 percent decrease. Gross margins decreased to 40 percent for the quarter compared to 43 percent for the same quarter of the prior year. SeraCare earned net income of $1.4 million and earnings per share on a basic and diluted basis of $0.07 for the quarter ended March 31, 2011 compared to net income of $2.1 million and earnings per share on a basic and diluted basis of $0.11 during the same period in fiscal 2010.  

Recent Corporate Highlights:

  • Achieved eighth consecutive quarter of profitability during the second quarter of fiscal 2011
  • Appointed a highly experienced Vice President of Sales and Marketing, Sean O'Connor. Mr. O'Connor, previously Director of Strategic Accounts at Ortho Clinical Diagnostics, a Johnson & Johnson company, brings more than 15 years of sales management experience in growing product revenues and creating new channel opportunities to SeraCare
  • Significantly expanded efforts to optimize the sales organization to drive growth, with a continued focus on diagnostics and pharmaceutical product sales in both North America and Europe
  • Introduced two new products in the second quarter of fiscal 2011
  • Increased cash balance to $16.9 million as of March 31, 2011
  • Generated $0.9 million in cash from operations during the quarter ended March 31, 2011, marking our ninth consecutive quarter of positive cash from operations
  • Added two new members to our Board of Directors, Kevin Hrusovsky and Joseph Nemmers—both with extensive experience in the life sciences industry

  • Conference Call Information:The conference call will be webcast live over the Internet and can be accessed by logging on to the "Investor Center, Events" section of the SeraCare Life Sciences website at The call can also be accessed by dialing (800) 638-4930 (within the United States) or (617) 614-3944 (outside the United States). The passcode for participants is 86383782.

    A replay of the call will be available approximately two hours after the live call concludes through May 19, 2011. To access the replay, dial (888) 286-8010 (within the United States) or (617) 801-6888 (outside the United States). The passcode is 31539364. The webcast will also be archived on the Company's website.

    About SeraCare Life Sciences, Inc.:SeraCare serves the global life sciences industry by providing vital products and services to facilitate the discovery, development and production of human diagnostics and therapeutics. The Company's innovative portfolio includes diagnostic controls, plasma-derived reagents and molecular biomarkers, biobanking and contract research services. SeraCare's quality systems, scientific expertise and state-of-the-art facilities support its customers in meeting the stringent requirements of the highly regulated life sciences industry.

    Forward-Looking Statements:This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about SeraCare Life Sciences, Inc. ("SeraCare" or the "Company"). All statements regarding our future financial position, results of operations, cash flows, dividends, financing plans, business strategy, budget, projected costs or cost savings, capital expenditures, competitive positions, growth opportunities for existing products or products under development, plans and objectives of management for future operations and markets for stock are forward-looking statements. In addition, forward-looking statements include statements in which we use words such as "expect," "believe," "anticipate," "intend," or similar expressions. Although we believe the expectations reflected in such forward-looking statements are based on reasonable assumptions, we cannot assure you that these assumptions will prove to have been correct, and actual results may differ materially from those reflected in the forward-looking statements. Factors that could cause our actual results to differ from the expectations reflected in the forward-looking statements in this press release include, but are not limited to, prolonged impairment of sales from changes in our sales organization, potential difficulties hiring sales personnel with the desired qualifications, revenue shortfalls arising from customer transitions to new products, unpredictability in large customer orders, failure to maintain proper inventory levels, availability of financing, reductions or terminations of government or other contracts, interruption in our supply of products or raw materials, actions of SeraCare's competitors, changes in the regulatory environment, delays in new product introductions, lack of market acceptance of new products, decreased healthcare spending, reduced margins resulting from a shift in revenue towards services, absence or loss of acquisition opportunities to higher bidders, potential failure to complete any announced acquisition, and potential failure of any acquisition to produce expected revenues, profits or synergies. Many of these factors are beyond our ability to control or predict.

    Gregory A. Gould
    Chief Financial Officer
    SeraCare Life Sciences, Inc.

    Sarah Cavanaugh
    MacDougall Biomedical Communications
    781-235-3060--Financial Tables to Follow--SERACARE LIFE SCIENCES, INC.STATEMENTS OF OPERATIONS — UNAUDITEDFor the Three Months EndedFor the Six Months EndedMarch 31,March 31,2011201020112010Revenue

    $ 11,002,884$ 12,851,370$ 21,465,381$ 24,108,475Cost of revenue

    6,603,4637,292,79213,098,07313,633,123Gross profit

    4,399,4215,558,5788,367,30810,475,352Research and development expense

    236,451168,332545,698331,605Selling, general and administrative expenses

    2,868,4203,407,8175,815,3486,668,223Reorganization items

    --(846,094)-Operating income

    1,294,5501,982,4292,852,3563,475,524Interest (expense) income, net

    (8,943)(25,925)13,339(230,650)Other income, net

    15,00027,61815,45230,083Income before income taxes

    1,300,6071,984,1222,881,1473,274,957Income tax benefit

    93,226112,22593,226103,925Net income

    $   1,393,833$   2,096,347$   2,974,373$   3,378,882Earnings per common share   Basic

    .18   Diluted

    .18Weighted average shares outstanding   Basic

    18,905,06218,828,19918,882,88818,783,747   Diluted

    19,311,93719,005,35319,286,98419,024,835SERACARE LIFE SCIENCES, INC.BALANCE SHEETS — UNAUDITEDAs OfAs OfMarch 31,September 30,20112010ASSETSCurrent assetsCash and cash equivalents

    $ 16,880,652$
    ,074,915Accounts receivable, less allowance for doubtful accounts of $40,000 as of  both March 31, 2011 and September 30, 2010

    6,838,6057,288,133Taxes receivable


    9,580,8819,028,809Prepaid expenses and other current assets

    246,701333,191Total current assets

    33,552,74932,843,534Property and equipment, net6,140,5615,970,179Goodwill4,284,9794,284,979Other assets470,422526,810Total assets$ 44,448,711$
    43,625,502LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilitiesAccounts payable

    $   1,891,533$
    2,787,855Accrued expenses and other liabilities

    2,378,7444,041,172Current portion of long-term debt

    43,47155,994Total current liabilities

    4,313,7486,885,021Long-term debt6,68421,970Other liabilities2,136,8352,216,916Total liabilities

    6,457,2679,123,907Commitments and contingenciesStockholders' equityPreferred stock, $.001 par value, 5,000,000 shares authorized; no shares   issued or outstanding

    --Common stock, $.001 par value, 35,000,000 shares authorized; 18,905,971   and 18,853,584 shares issued and outstanding as of March 31, 2011 and   September 30, 2010, respectively

    18,90618,853Additional paid-in-capital

    104,866,516104,351,093Retained deficit

    (66,893,978)(69,868,351)Total stockholders' equity

    37,991,44434,501,595Total liabilities and stockholders' equity$ 44,448,711$

    SOURCE SeraCare Life Sciences, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related biology technology :

    1. SeraCare Announces the Election of Joseph Nemmers and Kevin Hrusovsky to the Board of Directors
    2. SeraCare Life Sciences Appoints Sean OConnor as Vice President of Sales and Marketing
    3. SeraCare Reports First Quarter Fiscal Year 2011 Results
    4. SeraCare Life Sciences to Report First Quarter 2011 Financial Results on February 11, 2011
    5. SeraCare Life Sciences Secures $20 Million Credit Facilities
    6. PharmAthene Reports First Quarter 2011 Financial and Operating Results
    7. Micell Technologies Reports Preclinical Data for MiStentâ„¢ Drug-Eluting Coronary Stent to be Presented at EuroPCR
    8. BioSpecifics Technologies Corp. Reports First Quarter 2011 Financial Results
    9. Neuralstem Reports First Quarter Financial Results and Provides Business and Clinical Update
    10. GenVec Reports First Quarter 2011 Financial Results
    11. American Oriental Bioengineering Reports First Quarter 2011 Financial Results
    Post Your Comments:
    (Date:11/25/2015)... , ... November 25, 2015 , ... ... uBiome, were featured on AngelList early in their initial angel funding process. Now, ... syndicate for individuals looking to make early stage investments in the microbiome space. ...
    (Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... The United ... recipient of the 2016 USGA Green Section Award. Presented annually since 1961, the USGA ... his or her work with turfgrass. , Clarke, of Iselin, N.J., is ...
    (Date:11/24/2015)... , Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: ... in New York on Wednesday, December 2 ... Torley , president and CEO, will provide a corporate overview. ... York at 1:00 p.m. ET/10:00 a.m. PT . ... relations, will provide a corporate overview. --> th ...
    (Date:11/24/2015)... ... November 24, 2015 , ... ... But unless it is bound to proteins, copper is also toxic to cells. ... at Worcester Polytechnic Institute (WPI) will conduct a systematic study of copper in ...
    Breaking Biology Technology:
    (Date:10/27/2015)... , Oct. 27, 2015 In the ... issues of concern for various industry verticals such as ... due to the growing demand for secure & simplified ... various ,sectors, such as hacking of bank accounts, misuse ... electronic equipment such as PC,s, laptops, and smartphones are ...
    (Date:10/27/2015)... Synaptics Inc. (NASDAQ: SYNA ), the leader ... adopted the Synaptics ® ClearPad ® Series ... newest flagship smartphones, the Nexus 5X by LG and ... --> --> Synaptics works closely with ... in the joint development of next generation technologies. Together, ...
    (Date:10/26/2015)... LAS VEGAS , Oct. 26, 2015 ... an innovator in modern authentication and a founding member ... launch of its latest version of the Nok Nok™ ... to use standards-based authentication that supports existing and emerging ... Suite is ideal for organizations deploying customer-facing applications that ...
    Breaking Biology News(10 mins):